|Bid||30.13 x 900|
|Ask||30.50 x 1000|
|Day's Range||27.94 - 30.40|
|52 Week Range||2.52 - 35.02|
|Beta (5Y Monthly)||4.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul. 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.21|
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President, Chief Technology Officer (CTO) and Jayne M. Gansler as Executive Vice President, Chief People Officer (CPO).
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the presentation of previously announced positive Phase 3 results from the ECOSPOR III trial of SER-109 at the Virtual American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 23-28, 2020. New data to be presented in Seres’ late-breaker oral presentation show that SER-109 led to a sustained highly statistically significant absolute reduction in C. difficile infection recurrence at 12 weeks post-treatment when compared to placebo. Additionally, new findings demonstrate that SER-109 administration resulted in similar efficacy when stratified by age groups (i.e., > or <65 years) or prior antibiotic received (i.e., vancomycin or fidaxomicin).
The tech-heavy Nasdaq index posted its best third quarter in 10 years this year.